Literature DB >> 12547889

Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy.

Piero Ruggenenti1, Claudio Flores, Claudio Aros, Bogdan Ene-Iordache, Roberto Trevisan, Cosimo Ottomano, Giuseppe Remuzzi.   

Abstract

OBJECTIVE: To assess whether the insulin analog lispro may antagonize the renal effects of IGF-1, a mediator of glomerular hyperfiltration involved in the progression of diabetic and nondiabetic chronic nephropathies. RESEARCH DESIGN AND METHODS: In a randomized crossover study, we compared the renal and metabolic responses to regular or lispro insulin (0.1 units/kg body wt) administered after a euglycemic clamp and 5 and 30 min before a standard meal to 11 type 2 diabetic patients with macroalbuminuria.
RESULTS: Two- and four-hour postprandial changes (vs. preprandial euglycemia) in glomerular filtration rate (GFR) followed a significantly different trend (5.8 +/- 5.0 vs. -6.3 +/- 4.7, P < 0.05; and 11.0 +/- 6.8 vs. 0.7 +/- 5.1%, P < 0.05) after regular insulin and lispro injection, respectively. After lispro, postprandial GFR changes were negatively correlated (r = -0.48, P = 0.0001) with plasma insulin concentration. After regular insulin, renal plasma flow increased in parallel with a decrease in renal vascular resistances. Both changes were fully prevented by lispro. Postprandial blood glucose maximum concentration (278 +/- 16 vs. 240 +/- 16 mg/dl, P < 0.01) and area under the curve (79,381 +/- 19,237 vs. 72,810 +/- 16,211 mg/dl per min, P < 0,05) were significantly lower after insulin lispro than after regular insulin injection, respectively, despite comparable postprandial insulin profiles. Changes in total and gluconeogenic amino acids followed a similar trend. Changes in blood glucose and plasma amino acids did not correlate with concomitant changes in GFR.
CONCLUSIONS: In overt nephropathy of type 2 diabetes, lispro prevents glomerular hyperfiltration and offsets the renal effects of meal or meal-associated hyperglycemia by mechanisms possibly related to IGF-1 antagonism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547889     DOI: 10.2337/diacare.26.2.502

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  9 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

2.  Treatment with insulin analogs, especially Glargine and Lispro, associates with better renal function and higher hemoglobin levels in Type 1 diabetic patients with impaired kidney function.

Authors:  Christoph Hasslacher; Felix Kulozik; Justo Lorenzo Bermejo
Journal:  Ther Adv Endocrinol Metab       Date:  2016-05-15       Impact factor: 3.565

Review 3.  Management of diabetic kidney disease: Recent advances.

Authors:  Pankaj Agarwal
Journal:  Indian J Endocrinol Metab       Date:  2013-10

Review 4.  Interactions between kidney disease and diabetes: dangerous liaisons.

Authors:  Roberto Pecoits-Filho; Hugo Abensur; Carolina C R Betônico; Alisson Diego Machado; Erika B Parente; Márcia Queiroz; João Eduardo Nunes Salles; Silvia Titan; Sergio Vencio
Journal:  Diabetol Metab Syndr       Date:  2016-07-28       Impact factor: 3.320

Review 5.  Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control.

Authors:  Carolina C R Betônico; Silvia M O Titan; Maria Lúcia C Correa-Giannella; Márcia Nery; Márcia Queiroz
Journal:  Clinics (Sao Paulo)       Date:  2016-01       Impact factor: 2.365

6.  Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016.

Authors:  Julie Z Zhao; Eric D Weinhandl; Angeline M Carlson; Wendy L St Peter
Journal:  Kidney Med       Date:  2020-12-30

Review 7.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24

8.  A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease.

Authors:  Anirban Majumder; Soumyabrata RoyChaudhuri; Debmalya Sanyal
Journal:  Cureus       Date:  2019-11-18

Review 9.  Polyphenols with antiglycation activity and mechanisms of action: A review of recent findings.

Authors:  Wan-Ju Yeh; Shih-Min Hsia; Wei-Hwa Lee; Chi-Hao Wu
Journal:  J Food Drug Anal       Date:  2016-12-05       Impact factor: 6.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.